Innovative Bispecific Nanobody Targeting CD33 and IL3RA for Acute Myeloid Leukemia Therapy

VHH-P205 is a humanized, bispecific single-domain antibody-fusion molecule precisely engineered to target both the CD33 molecule (CD33) and interleukin 3 receptor subunit alpha (IL3RA). Currently in the Biological Testing stage, this advanced biologic is designed for the potential treatment of acute myeloid leukemia. By leveraging the dual-targeting capability, VHH-P205 offers a novel approach to engage multiple disease-associated antigens, aiming to improve treatment outcomes for patients with limited therapeutic options. The construct combines specificity, modularity, and a favorable biotechnological profile suitable for rigorous preclinical and clinical development.

Licensing Opportunity

VHH-P205 is currently open for out-licensing and strategic collaborations. We welcome inquiries from partners interested in the development and commercialization of innovative bispecific nanobody therapies for hematological malignancies.

Development Phase

Modality

VHH-P205 is a bispecific Fc fusion antibody that merges a codon-optimized, humanized single-domain antibody targeting CD33 with a humanized VHH targeting IL3RA, both linked via a human IgG1 Fc domain and produced in Escherichia coli. The nanobody format provides structural advantages, including a reduced molecular size and enhanced stability, which can improve tissue penetration and target accessibility in solid and hematologic malignancies such as acute myeloid leukemia. This innovative modality supports efficient engineering and manufacturability, while the bispecific design allows for the simultaneous engagement of two validated oncogenic markers, offering potential improvements in disease specificity and efficacy.

Target

CD33 and IL3RA are both cell surface molecules prominently associated with acute myeloid leukemia. CD33 is a transmembrane receptor expressed mainly on myeloid lineage cells and is present on leukemic blasts in the majority of acute myeloid leukemia cases. IL3RA, likewise, is highly expressed on leukemic progenitors and plays a role in malignant cell proliferation and survival. The selective targeting of CD33 and IL3RA exploits their restricted expression pattern in malignant versus normal hematopoietic populations, reducing risk to healthy tissues. By focusing on CD33 and IL3RA, VHH-P205 addresses critical pathways central to leukemogenesis, reinforcing their strategic value for therapeutic intervention and supporting the potential for greater clinical benefit in acute myeloid leukemia.

Mechanism of Action

VHH-P205 functions through high-affinity engagement with both CD33 and IL3RA, modulating key signal transduction pathways involved in leukemic cell survival and proliferation. By simultaneously binding CD33 and IL3RA, the bispecific nanobody inhibits oncogenic signaling cascades and may enhance immune effector recruitment through its Fc fusion design. This dual targeting disrupts tumor cell growth and may induce cytotoxic mechanisms, supporting a more comprehensive anti-leukemic effect compared to monospecific agents. The robust platform underlying VHH-P205 also permits adaptation as a scaffold for next-generation modalities, such as antibody-drug conjugates or multispecific antibodies, further underlining its potential in hematologic cancers.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive malignancy originating from the clonal proliferation of abnormal myeloid precursors in the bone marrow, resulting in impaired hematopoiesis and rapid clinical progression. AML affects both pediatric and adult populations, with higher incidence in older adults, and presents significant treatment challenges due to disease heterogeneity and high relapse rates. Standard care typically relies on intensive chemotherapy and, for eligible patients, hematopoietic stem cell transplantation. While targeted therapies have begun to change the treatment landscape, long-term outcomes in relapsed or refractory AML remain poor and significant toxicity limits broader use. There is a substantial unmet medical need for more precise and effective therapeutics that can selectively eliminate leukemic cells while minimizing off-target effects. VHH-P205, by targeting CD33 and IL3RA, addresses these gaps with a rational strategy aimed at dual pathway inhibition and enhanced leukemic cell killing, holding promise for improved patient outcomes and greater therapeutic selectivity.